BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25055481)

  • 1. [The affair "Crispr-Cas9" or genetically enhanced humanity].
    Nau JY
    Rev Med Suisse; 2014 Jun; 10(436):1428-9. PubMed ID: 25055481
    [No Abstract]   [Full Text] [Related]  

  • 2. CRISPR adaptation in Escherichia coli subtypeI-E system.
    Kiro R; Goren MG; Yosef I; Qimron U
    Biochem Soc Trans; 2013 Dec; 41(6):1412-5. PubMed ID: 24256229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new method in biotechnology].
    Hofmann-Aßmus M
    MMW Fortschr Med; 2015 Apr; 157(7):75. PubMed ID: 26012467
    [No Abstract]   [Full Text] [Related]  

  • 4. Editing and investigating genomes with TALE and CRISPR/Cas systems: applications of artificial TALE and CRISPR-Cas systems.
    Giovannangeli C; Concordet JP
    Methods; 2014 Sep; 69(2):119-20. PubMed ID: 25248487
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system.
    Liang Z; Zhang K; Chen K; Gao C
    J Genet Genomics; 2014 Feb; 41(2):63-8. PubMed ID: 24576457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary causes and consequences of diversified CRISPR immune profiles in natural populations.
    England WE; Whitaker RJ
    Biochem Soc Trans; 2013 Dec; 41(6):1431-6. PubMed ID: 24256233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The revolution of the CRISPR is underway].
    Gilgenkrantz H
    Med Sci (Paris); 2014 Dec; 30(12):1066-9. PubMed ID: 25537031
    [No Abstract]   [Full Text] [Related]  

  • 8. One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system.
    Wan H; Feng C; Teng F; Yang S; Hu B; Niu Y; Xiang AP; Fang W; Ji W; Li W; Zhao X; Zhou Q
    Cell Res; 2015 Feb; 25(2):258-61. PubMed ID: 25430965
    [No Abstract]   [Full Text] [Related]  

  • 9. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant genome engineering in full bloom.
    Lozano-Juste J; Cutler SR
    Trends Plant Sci; 2014 May; 19(5):284-7. PubMed ID: 24674878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.
    Gori JL; Hsu PD; Maeder ML; Shen S; Welstead GG; Bumcrot D
    Hum Gene Ther; 2015 Jul; 26(7):443-51. PubMed ID: 26068008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Transcriptional Repression in Bacteria Using CRISPR Interference (CRISPRi).
    Hawkins JS; Wong S; Peters JM; Almeida R; Qi LS
    Methods Mol Biol; 2015; 1311():349-62. PubMed ID: 25981485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted genome editing in primate embryos.
    Guo X; Li XJ
    Cell Res; 2015 Jul; 25(7):767-8. PubMed ID: 26032266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five big mysteries about CRISPR's origins.
    Ledford H
    Nature; 2017 Jan; 541(7637):280-282. PubMed ID: 28102279
    [No Abstract]   [Full Text] [Related]  

  • 15. [Not Available].
    Nau JY
    Rev Med Suisse; 2016 Apr; 12(514):766-7. PubMed ID: 27263157
    [No Abstract]   [Full Text] [Related]  

  • 16. The combinational use of CRISPR/Cas9-based gene editing and targeted toxin technology enables efficient biallelic knockout of the α-1,3-galactosyltransferase gene in porcine embryonic fibroblasts.
    Sato M; Miyoshi K; Nagao Y; Nishi Y; Ohtsuka M; Nakamura S; Sakurai T; Watanabe S
    Xenotransplantation; 2014; 21(3):291-300. PubMed ID: 24919525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parasite Exposure Drives Selective Evolution of Constitutive versus Inducible Defense.
    Westra ER; van Houte S; Oyesiku-Blakemore S; Makin B; Broniewski JM; Best A; Bondy-Denomy J; Davidson A; Boots M; Buckling A
    Curr Biol; 2015 Apr; 25(8):1043-9. PubMed ID: 25772450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into the inactivation of CRISPR-Cas systems by diverse anti-CRISPR proteins.
    Zhu Y; Zhang F; Huang Z
    BMC Biol; 2018 Mar; 16(1):32. PubMed ID: 29554913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic correction using engineered nucleases for gene therapy applications.
    Li HL; Nakano T; Hotta A
    Dev Growth Differ; 2014 Jan; 56(1):63-77. PubMed ID: 24329887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9-based photoactivatable transcription system.
    Nihongaki Y; Yamamoto S; Kawano F; Suzuki H; Sato M
    Chem Biol; 2015 Feb; 22(2):169-74. PubMed ID: 25619936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.